Abstract:To explore the value of diffusion-weighted magnetic resonance imaging (DW-MRI) and 18F- Fluorodeoxyglucose (FDG) PET for the prediction of response to neoadjuvant chemoradiotherapy (nCRT) in potentially resectable locally advanced esophageal squamous cell carcinoma (ESCC). From December 2018 to October 2019, twenty-two patients with histologically proven locally advanced (T3-4N1-2M0) ESCC were enrolled. All patients received 23 fractions of 1.8 Gy (DT 41.4 Gy) external-beam intensity modulated radiotherapy combined with concurrent weekly administered paclitaxel (45 mg/m2) and cisplatin (20 mg/m2). DW-MRI scanning was performed before nCRT, after 10–15 fractions, and 4-6 weeks after nCRT. The apparent diffusion coefficient (ADC) of primary tumor was evaluated at these three time points. All patients had a pre-nCRT before nCRT and a post-nCRT PET scan 4-6 weeks after nCRT. The metabolic tumor volume (MTV) was measured using a minimum standardized uptake value (SUV) threshold 2.5 and the total glycolytic activity (TGA) was defined as the mean SUV×MTV. 4 in 22 patients (18.2%) did not receive surgery for the progressive disease after neoadjuvant chemoradiotherapy with new distant metastases detected by post-nCRT FDG-PET. Among the 18 patients who underwent radical resection, 5 patients (27.8%) achieved pathological complete response (pCR) and another 2 patients were found complete response in primary lesion but positive lymph nodes. The postSUVmax, postMTV and postTGA were significantly lower in patients with non-progressive disease (non-PD) vs. patients with progressive disease (PD) (p= 0.001, p=0.004, p=0.005), as well as in pCR vs. non-pCR patients(p=0.043, p=0.001, p=0.011). The ADC value increased significantly during the neoadjuvant chemoradiotherapy in non-PD patients (1.40±0.37 vs. 2.21±0.49, p=0.00), but not in the PD patients(1.47±0.48 vs. 1.72±0.22, p=0.27). The ADCduring was also significantly higher in patients with primary lesion complete response than that of patients with residual tumor(2.68±0.32 vs. 2.09±0.40, p=0.005). However, all these parameters of FDG-PET and DW-MRI before nCRT had no differences between these groups. FDG-PET after neoadjuvant chemoradiotherapy detected distant metastases during nCRT to avoid non-curative resections and the SUVmax, MTV and TGA of post-nCRT PET varied with pathological response. The ADC value in DW-MRI at the first 2–3 weeks of nCRT seemed to be the early predictive factor of nCRT response. Larger series are needed to confirm these results.

[Endoscopic response evaluation in gastrointestinal cancers after neoadjuvant chemora- diotherapy]

Tumor pathological response and downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: comparison of two radiation dose schedules

Changing Patterns of Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Narrative Review

On Predicting Clinical Response to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Additional Evaluation by Magnetic Resonance Imaging May Help

Research Progress of Neoadjuvant Therapy for Locally Advanced Rectal Cancer

[Radiological Evaluation on the Efficacy of Neoadjuvant Therapy for Gastrointestinal Tumors].

Patients Selection and Response Evaluation in Neoadjuvant Chemoradiation of Rectal Cancer

Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study

Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review.

A Review Of Neoadjuvant Chemoradiotherapy For Locally Advanced Rectal Cancer

Biomarkers for the prediction of esophageal cancer neoadjuvant chemoradiotherapy response: A systemic review.

[Imaging Evaluation of Response of Rectal Cancer to Preoperative Chemoradiotherapy].

Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer

Diffusion-Weighted MRI and (18)F-Fdg PET/CT in Assessing Response to Neoadjuvant Chemoradiotherapy in Potentially Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Current neoadjuvant therapy for operable locally advanced esophageal cancer

Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma

Early Response Evaluation of Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer Using T1 and T2 Mapping

[Advances of Optimized Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer].

Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review

[The Role of Neoadjuvant Therapy in Multimodality Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: Perspective from the NEOCRTEC5010 Trial].